Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

NCT03521830 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Basal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Relatlimab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]